GSK Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de GSK de 9.3% y 4.5% por año respectivamente. Se prevé que el BPA crezca en un 9.1% al año. Se espera que la rentabilidad financiera sea de 33.9% en 3 años.

Información clave

9.3%

Tasa de crecimiento de los beneficios

9.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	14.8%
Tasa de crecimiento de los ingresos	4.5%
Rentabilidad financiera futura	33.9%
Cobertura de analistas	Good
Última actualización	23 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Previsiones de crecimiento de beneficios e ingresos

LSE:GSK - Estimaciones futuras de los analistas y datos financieros pasados (GBP Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	35,240	7,107	7,658	9,860	19
12/31/2025	33,379	6,397	7,187	9,313	21
12/31/2024	31,478	5,664	6,661	8,541	21
12/31/2023	30,328	4,928	4,436	6,768	N/A
9/30/2023	29,652	6,078	3,247	5,477	N/A
6/30/2023	29,334	5,373	2,486	4,586	N/A
3/31/2023	29,085	4,455	2,892	4,914	N/A
12/31/2022	29,324	4,461	5,341	7,403	N/A
9/30/2022	29,024	3,387	7,620	9,265	N/A
6/30/2022	27,822	3,505	8,073	10,506	N/A
3/31/2022	26,731	4,013	7,611	10,163	N/A
12/31/2021	24,696	3,316	5,939	7,952	N/A
9/30/2021	26,359	3,567	6,064	8,040	N/A
6/30/2021	28,378	3,934	4,871	6,339	N/A
3/31/2021	30,164	4,983	7,028	7,807	N/A
12/31/2020	24,354	4,873	6,839	8,441	N/A
9/30/2020	34,259	6,371	6,833	8,039	N/A
6/30/2020	34,998	6,679	8,751	9,693	N/A
3/31/2020	35,183	5,380	6,628	8,322	N/A
12/31/2019	33,754	4,645	6,261	8,020	N/A
9/30/2019	33,052	4,561	6,832	8,686	N/A
6/30/2019	31,759	4,427	6,488	8,248	N/A
3/31/2019	31,260	3,904	6,735	8,221	N/A
12/31/2018	30,821	3,623	6,881	8,421	N/A
9/30/2018	30,263	1,862	5,521	7,171	N/A
6/30/2018	30,014	1,656	5,140	6,991	N/A
3/31/2018	30,024	1,035	4,549	6,637	N/A
12/31/2017	30,186	1,532	4,764	6,918	N/A
9/30/2017	30,133	2,335	N/A	7,040	N/A
6/30/2017	29,832	1,931	N/A	6,910	N/A
3/31/2017	29,044	1,676	N/A	7,138	N/A
12/31/2016	27,889	912	N/A	6,497	N/A
9/30/2016	26,589	301	N/A	5,007	N/A
6/30/2016	25,174	31	N/A	3,721	N/A
3/31/2016	24,530	615	N/A	2,702	N/A
12/31/2015	23,923	8,422	N/A	2,569	N/A
9/30/2015	23,823	9,809	N/A	3,278	N/A
6/30/2015	23,342	9,672	N/A	4,070	N/A
3/31/2015	23,015	10,177	N/A	4,619	N/A
12/31/2014	23,006	2,756	N/A	5,176	N/A
9/30/2014	23,726	4,184	N/A	5,153	N/A
6/30/2014	24,590	4,752	N/A	5,957	N/A
3/31/2014	25,647	5,143	N/A	6,902	N/A
12/31/2013	26,505	5,436	N/A	7,222	N/A
9/30/2013	26,401	3,823	N/A	6,949	N/A
6/30/2013	26,418	3,959	N/A	4,584	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (9.3% al año) de GSK es superior a la tasa de ahorro (1.6%).

Beneficios vs. Mercado: Se prevé que los beneficios (9.3% al año) de GSK crezcan menos que el mercado UK (12.2% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de GSK crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (4.5% al año) de GSK crezcan más rápidamente que los del mercado UK (3.3% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 4.5% al año) de GSK crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de GSK sea alta dentro de 3 años (33.9%)

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

GSK Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

GSK plc Provides Earnings Guidance for the Year 2024

Price target increased by 10% to UK£19.22

Gsk plc Revises Earnings Guidance for the Full Year 2023

Recent updates

GSK plc Announces the US Food and Drug Administration Accepted the Supplemental Biologics License Application for Jemperli

These 4 Measures Indicate That GSK (LON:GSK) Is Using Debt Reasonably Well

GSK plc Announces Positive Results from the Pivotal Eagle-1 Phase III Trial for Gepotidacin

GSK plc Announces US Food and Drug Administration Accepts for Review Biologics License Application for its 5-in-1 Meningococcal ABCWY (MenABCWY) Vaccine Candidate

GSK plc, Annual General Meeting, May 08, 2024

GSK plc Appoints Hal Dietz as Member of Nominations & Corporate Governance Committee, Effective 11 March 2024

GSK plc Announces Positive Headline Results from an Interim Analysis of the Dreamm-8 Phase Iii Head-To-Head Trial Evaluating Blenrep (Belantamab Mafodotin)

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Reaches a Confidential Settlement with Boyd/Steenvoord

CEO & Director exercised options and sold UK£2.3m worth of stock

GSK plc (LSE:GSK) completed the acquisition of Aiolos Bio, Inc. from a group of shareholders.

Upcoming dividend of UK£0.16 per share at 3.5% yield

GSK plc Receives US Food and Drug Administration Fast Track Designation for Bepirovirsen in Chronic Hepatitis B

Center for Drug Evaluation Accepts to Review GSK's Regulatory Application for Shingrix for the Prevention of Shingles in at-Risk Adults Aged 18 and over

GSK's (LON:GSK) Solid Earnings Are Supported By Other Strong Factors

Gsk plc Announces Results from an Interim Analysis of The DREAMM-7 Phase III Head-To-Head Trial

GSK plc to Report Q1, 2024 Results on May 01, 2024

Fourth quarter dividend of UK£0.16 announced

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

GSK plc Provides an Update on Zantac (Ranitidine) Litigation

GSK plc Provides Earnings Guidance for the Year 2024

European Medicines Agency Accepts GSK's Arexvy Filing for Adults 50-59 At Risk

Price target increased by 10% to UK£19.22

We Think GSK (LON:GSK) Can Stay On Top Of Its Debt

GSK plc to Report Q4, 2023 Results on Jan 31, 2024

GSK plc (LSE:GSK) entered into an agreement to acquire Aiolos Bio, Inc. from a group of shareholders for $1.4 billion.

Insufficient Growth At GSK plc (LON:GSK) Hampers Share Price

GSK plc Announces Positive Headline Results from Planned Analysis of Part 2 of the RUBY/ENGOT-EN6/GOG3031/NSGO Phase III Trial

GSK plc Announces Japan's Ministry of Health, Labour and Welfare Accepts Arexvy Regulatory Application to Prevent RSV Disease in Adults Aged 50-59 At Increased Risk

Japan's Ministry of Health, Labour and Welfare Accepts Arexvy Regulatory Application to Prevent RSV Disease in Adults Aged 50-59 At Increased Risk

Gsk plc Announces It's Jemperli (Dostarlimab) Plus Chemotherapy Approved as the First and Only Frontline Immuno-Oncology Treatment in the European Union for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

GSK plc Announces Positive Results from DREAMM-7 Head-To-Head Phase III Trial for Blenrep in Relapsed/Refractory Multiple Myeloma

GSK plc Announces Positive Results from DREAMM-7 Head-To-Head Phase III Trial for Blenrep in Relapsed/Refractory Multiple Myeloma

GSK Receives Positive CHMP Opinion Recommending Momelotinib for Myelofibrosis Patients with Anaemia

Upcoming dividend of UK£0.14 per share at 4.3% yield

GSK (LON:GSK) Has Announced A Dividend Of £0.14

Gsk plc Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Gsk plc Announces Positive Headline Results from Planned Analysis of Part 1 of the Ruby/Engot-En6/Gog3031/Nsgo Phase Iii Trial

GSK plc Announces Positive Preliminary Results from its Phase III Trial Evaluating the Immune Response and Safety of Arexvy

GSK plc Receives Positive CHMP Opinion Recommending Approval of Jemperli (Dostarlimab) Plus Chemotherapy as A New Frontline Treatment for DMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer

GSK plc Announces Update on Zantac (Ranitidine) Litigation

An unknown buyer acquired a 2.923787% stake in Haleon plc from GSK plc for approximately £890 million.

GSK plc to Report Q3, 2023 Results on Nov 01, 2023

Is GSK (LON:GSK) A Risky Investment?

GSK plc Announces Board Changes

GSK plc Announces Japan's Ministry of Health, Labour and Welfare Approves Arexvy for the Prevention of RSV

US Food and Drug Administration Approves GSK Plc's Ojjaara (Momelotinib) for the Treatment of Intermediate or High-Risk Myelofibrosis, Including Primary Myelofibrosis or Secondary Myelofibrosis

GSK Regulatory Submission for Momelotinib for the Treatment of Myelofibrosis Accepted for Review by Japanese Regulator

Gsk plc Announces Nucala Crswnp Submission Accepted in Japan

GSK plc Announces Positive Results from the First-Ever Efficacy Trial of Shingrix in China

GSK plc Announces AREXVY, Respiratory Syncytial Virus Vaccine, Available At All Major US Retail Pharmacies

Upcoming dividend of UK£0.14 per share at 4.4% yield

GSK plc Announced That the US Food and Drug Administration Approved Jemperli (Dostarlimab) in Combination with Carboplatin and Paclitaxe

GSK plc Announces Dividend for Second Quarter of 2023, Payable on 12 October 2023

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento